Teva Pharma is trading at $41.59 (+4.07%), with healthcare’s advance the clearest available context for the gain. - Healthcare rose 2.32%, helped by strong earnings and outlooks from Merck and Eli Lilly. - Broader U.S. markets traded lower. - Teva’s BioXcel asset acquisition was reported earlier, but available coverage does not establish it as the cause of the October 29 gain or identify a new Teva-specific catalyst.